A1M Pharma to participate at the Rodman & Renshaw Global Investment Conference in New York

"I am looking forward to present our research at such a well-known and established forum as the Rodman & Renshaw Global Investment Conference. It is a great opportunity to strengthen the international awareness of the company, and it is entirely in line with our ambition to attract foreign investors", says Martin Austin, A1M Pharma's Chairman of the Board.

At the conference, A1M Pharma will present an overview of the company, including its current projects under development, and prospects for the future. Martin Austin, A1M Pharmas Chairman of the Board, will represent the company at the event. A1M Pharma will also attend one-on-one meetings with investors who are registered to participate at the conference. The presentation will also be broadcasted live on the web. To access the webcast, please visit www.rodmanevents.com. The webcast will remain available for 90 days following the presentation.

A1M Pharma is presenting on: Tuesday September 12th at 22:40-23:05 (4:40-5:05 local time)

About Rodman & Renshaw Global Investment Conference
The Rodman & Renshaw Global Investment Conference will feature over 300 presenting companies and 2,000 attendees, bringing growth companies together with a large number of financial and strategic investors. Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. In the first half of 2017, they have helped their clients bring in $ 2.4 billion, divided on 68 transactions.

2017-08-29

For more information, please contact
Tomas Eriksson, CEO
Telephone: +46 46-286 50 30
Email: [email protected]

The following documents can be retrieved from beQuoted
A1M Pharma Pressrelease 2017-08-29 English.pdf

About A1M
Pharma Several preclinical studies indicate that A1M Pharma's candidate drug, ROSGard™, based on the endogenous protein Alpha- 1-Microglobulin, restores impairments to kidney function by repairing damaged tissue and protecting against oxidative stress. Kidney injury is a condition which often occurs in connection with preeclampsia and which often limits the possibilities of using radiation therapies as a treatment for cancer. The company's two indications are kidney protection in connection with Peptide Receptor Radionuclide Therapy (PRRT) - a targeted radiation therapy for cancer - with the aim of opening the possibility of increasing treatment levels and so fight metastatic cancer more effectively as well as treatment of preeclampsia. Every year, over 12 million people are affected by acute kidney injuries that can lead to permanent kidney damage. Preeclampsia affects around 10 million pregnant women worldwide and is responsible for 76,000 maternal and 500,000 infant deaths each year. A1M Pharma is listed on Nasdaq First North Stockholm since 20 June 2017. A1M Pharma's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.

If you want to open the text in your webbrowser click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected]

beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.

Vi hoppas att Du uppskattar denna service.